Data from Pharmawand - Curated by Toby Galbraith - Date added 07 August 2017

Pfizer Inc. announced that FDA Arthritis Advisory Committee (AAC) voted 10 to 1 to recommend approval of the proposed dose of tofacitinib for the treatment of adult patients with active psoriatic arthritis. (PsA). Pfizer submitted supplemental new drug applications (sNDAs) for Zeljanz 5 mg twice daily (BID) and Xeljanz XR extended release 11 mg once daily (QD) for this pending indication.

The role of the Advisory Committee is to provide recommendations to the FDA. The FDA decision on whether to approve tofacitinib for PsA is anticipated by December 2017. If approved, tofacitinib would be the first Janus kinase (JAK) inhibitor for psoriatic arthritis.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress.

Visit IL-17A in Psoriasis


See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

Visit Psoriasis

Related Content